- Home
- CNTA vs HCM Comparison
CNTA vs HCM Comparison
Compare CNTA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- HCM
- Stock Information
- Founded
- CNTA 2020
- HCM 2000
- Country
- CNTA United Kingdom
- HCM Hong Kong
- Employees
- CNTA N/A
- HCM N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- CNTA Health Care
- HCM Health Care
- Exchange
- CNTA Nasdaq
- HCM Nasdaq
- Market Cap
- CNTA 2.3B
- HCM 2.6B
- IPO Year
- CNTA 2021
- HCM N/A
- Fundamental
- Price
- CNTA $22.74
- HCM $15.42
- Analyst Decision
- CNTA Strong Buy
- HCM Sell
- Analyst Count
- CNTA 8
- HCM 1
- Target Price
- CNTA $31.29
- HCM $13.75
- AVG Volume (30 Days)
- CNTA 995.9K
- HCM 47.5K
- Earning Date
- CNTA 11-11-2025
- HCM 08-07-2025
- Dividend Yield
- CNTA N/A
- HCM N/A
- EPS Growth
- CNTA N/A
- HCM N/A
- EPS
- CNTA N/A
- HCM 0.53
- Revenue
- CNTA $15,000,000.00
- HCM $602,197,000.00
- Revenue This Year
- CNTA N/A
- HCM N/A
- Revenue Next Year
- CNTA N/A
- HCM $15.49
- P/E Ratio
- CNTA N/A
- HCM $5.58
- Revenue Growth
- CNTA 118.88
- HCM N/A
- 52 Week Low
- CNTA $9.60
- HCM $11.51
- 52 Week High
- CNTA $24.57
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- CNTA 56.30
- HCM 43.73
- Support Level
- CNTA $21.78
- HCM $14.99
- Resistance Level
- CNTA $23.08
- HCM $16.40
- Average True Range (ATR)
- CNTA 1.00
- HCM 0.33
- MACD
- CNTA -0.28
- HCM -0.08
- Stochastic Oscillator
- CNTA 35.84
- HCM 30.14
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.